Skip to content

Inhalation or nasal corticosteroids and prevalence of hypothalamic-pituitary-adrenal axis suppression in HIV-infected patients

Inhalation or nasal corticosteroids and prevalence of hypothalamic-pituitary-adrenal axis suppression in HIV-infected patients - incorporate

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON42012
Enrollment
30
Registered
2015-03-10
Start date
2015-08-10
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adrenal insufficiency

Interventions

an ACTH stimulation test, cortisol measurements in blood and hair.

Sponsors

Universitair Medisch Centrum Sint Radboud
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Receive a treatment for HIV-infection - > 18 years old - Current usage of inhalation or nasal corticosteroids - Willing to give informed consent

Exclusion criteria

Exclusion criteria: - Known adrenal insufficiency - Concurrent use of topical corticosteroids, usage of oral corticosteroids in the last three months. Intramuscular or intra-articular corticosteroid injections in the last year. - Contra-indications for tetracosactide: allergy for tetracosactide, Cushings*s syndrome, refractory heart failure, peptic ulcer, acute psychosis, adrenogenital syndrome - Pregnant female or breast-feeding female. - Use of oral contraceptives, since these can heighten the cortisol-binding globulin

Design outcomes

Primary

MeasureTime frame
Proportions of persons with a low morning plasma cortisol or low cortisol after an ACTH stimulation test.

Secondary

MeasureTime frame
b. Proportions of persons with a low morning plasma cortisol or low cortisol after an ACTH stimulation test, stratified e.g. by kind of inhalation corticosteroid, dosage of local corticosteroid and use/no use of CYp3A4 inhibitor. c. Correlation between cortisol in plasma and hair cortisol.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)